The role of free prostate-specific antigen in the diagnosis of prostate cancer

British Journal of Urology

Volumn 79, Issue 6, 1997, Pages 920-923

  Akdas, A ^a   Cevik, I ^a   Tarcan, T ^a   Turkeri, L ^a   Dalaman, G ^a   Emerk, K ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Diagnosis; Free total PSA; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC;

EID: 0031396615     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00183.x     Document Type: Article

References (19)

1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-63
2. Nadji M, Tabei SZ, Castro A et ed. Prostate specific antigen: an immunohistologic marker for prostatic neoplasm. Cancer 1981; 48: 1229-32
3. Lilja H. Significance of different molecular forms of serum PSA. Urol Clin North Am 1993; 20: 681-6
4. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate specific antigen and α-1-antichymotrypsin is the major form of prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6
5. Stamey TA, Chen Z, Prestigiacomo A. Serum prostate specific antigen binding to a-1-antichymotrypsin: influence of cancer volume location and therapeutic selection of resistant clones. J Urol 1994; 152: 1510-4
6. Lilja H, Christensson A, Dahlen U et al. Prostate specific antigen in serum occurs predominantly in complex with α-1-antichymotrypsin. Clin Chem 1991; 37: 1618-25
7. Christensson A, Bjork T, Nilsson O et al. Serum prostate specific antigen complexed to a-1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-5
8. Benson MC, Whang IS, Pantuck A. Prostate specific antigen density: means of distinguishing benign prostatic hypertrophy in prostate cancer. J Urol 1992; 147: 815-6
9. Tchetgen MB, Oesterling JE. The role of prostate specific antigen in the evaluation of benign prostatic hyperplasia. Urol Clin North Am 1994; 22: 333-44
10. Chu TM, Murphy GP. What's new in tumor markers for prostate cancer? Urology 1986; 27: 487-91
11. Guinan P, Bhatti R, Ray P. An evaluation of prostate-specific antigen in prostatic cancer. J Urol 1987; 137: 686-9
12. Lange PH, Brawer MK. Serum prostate specific antigen: its use in diagnosis and management of prostate cancer. Urology 1989; 33 (suppl): 13-7
13. Lange PH. Prostate specific antigen in diagnosis and management of prostate cancer. Urology 1990; 36 (suppl 5): 25-9
14. Takayama TK, Vessella RL, Lange PH. Newer applications of serum prostate specific antigen in the management of prostate cancer. Semin Oncol 1994; 21: 542-53
15. Carter HB, Pearson JD, Metter JE et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992, 267: 2215-20
16. Oesterling JE, Jacopsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age specific reference ranges. JAMA 1993; 270: 860-4
17. Oesterling JE, Jacopsen SJ, Klee GG et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154: 1090-5
18. Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20
19. Luderer AA, Chen YT, Soriano TF et al. Measurement of the proportion of free to total prostate specific antigen improves diagnostic performance of prostate specific antigen in the diagnostic gray zone of total prostate specific antigen. Urology 1995; 46: 187-94 A. Akdas, MD, Chairman, Professor of Urology. I. Cevik, MD, Resident in Urology. T. Tarcan, MD, Resident in Urology. L. Turkeri, MD, Associate Professor of Urology. G. Dalaman, MD, Resident in Biochemistry. K. Emerk, MD, Chairman, Professor of Biochemistry. Correspondence: Dr A. Akdas, Marmara University School of Medicine, Department of Urology. Tophanelioglu cad. No: 13-1581190 Altunizade, Istanbul, Turkey.